Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 17.564
Filter
1.
Sci Rep ; 14(1): 12737, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38830922

ABSTRACT

The COVID-19 pandemic has altered the infection landscape for many pathogens. This retrospective study aimed to compare Haemophilus influenzae (H. influenzae) infections in pediatric CAP patients hospitalized before (2018-2019) and during (2020-2022) the COVID-19 pandemic. We analyzed the clinical epidemiology and antimicrobial resistance (AMR) patterns of H. influenzae from a tertiary hospital in southwest China. A total of 986 pediatric CAP patients with H. influenzae-associated infections were included. Compared to 2018, the positivity rate increased in 2019 but dropped significantly in 2020. Although it rose in the following 2 years, the rate in 2022 remained significantly lower than in 2019. Patients' age during the pandemic was significantly higher than in 2018 and 2019, while gender composition remained similar across both periods. Notably, there were significant changes in co-infections with several respiratory pathogens during the pandemic. Resistance rates of H. influenzae isolates to antibiotics varied, with the highest resistance observed for ampicillin (85.9%) and the lowest for cefotaxime (0.0%). Resistance profiles to various antibiotics underwent dramatic changes during the COVID-19 pandemic. Resistance to amoxicillin-clavulanate, cefaclor, cefuroxime, trimethoprim-sulfamethoxazole, and the proportion of multi-drug resistant (MDR) isolates significantly decreased. Additionally, MDR isolates, alongside isolates resistant to specific drugs, were notably prevalent in ampicillin-resistant and ß-lactamase-positive isolates. The number of pediatric CAP patients, H. influenzae infections, and isolates resistant to certain antibiotics exhibited seasonal patterns, peaking in the winter of 2018 and 2019. During the COVID-19 pandemic, sharp decreases were observed in February 2020, and there was no resurgence in December 2022. These findings indicate that the COVID-19 pandemic has significantly altered the infection spectrum of H. influenzae in pediatric CAP patients, as evidenced by shifts in positivity rate, demographic characteristics, respiratory co-infections, AMR patterns, and seasonal trends.


Subject(s)
Anti-Bacterial Agents , COVID-19 , Community-Acquired Infections , Haemophilus Infections , Haemophilus influenzae , Humans , COVID-19/epidemiology , COVID-19/complications , Male , Female , Haemophilus influenzae/drug effects , Haemophilus influenzae/isolation & purification , Child , Child, Preschool , Haemophilus Infections/epidemiology , Haemophilus Infections/drug therapy , Haemophilus Infections/microbiology , Retrospective Studies , Community-Acquired Infections/epidemiology , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Infant , China/epidemiology , Anti-Bacterial Agents/therapeutic use , Hospitalization , Adolescent , Pandemics , Coinfection/epidemiology , Coinfection/drug therapy , Coinfection/microbiology , SARS-CoV-2/isolation & purification , SARS-CoV-2/drug effects , Drug Resistance, Bacterial
2.
Sci Rep ; 14(1): 12726, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38830925

ABSTRACT

Improved phenotyping in pneumonia is necessary to strengthen risk assessment. Via a feasible and multidimensional approach with basic parameters, we aimed to evaluate the effect of host response at admission on severity stratification in COVID-19 and community-acquired pneumonia (CAP). Three COVID-19 and one CAP multicenter cohorts including hospitalized patients were recruited. Three easily available variables reflecting different pathophysiologic mechanisms-immune, inflammation, and respiratory-were selected (absolute lymphocyte count [ALC], C-reactive protein [CRP] and, SpO2/FiO2). In-hospital mortality and intensive care unit (ICU) admission were analyzed as outcomes. A multivariable, penalized maximum likelihood logistic regression was performed with ALC (< 724 lymphocytes/mm3), CRP (> 60 mg/L), and, SpO2/FiO2 (< 450). A total of 1452, 1222 and 462 patients were included in the three COVID-19 and 1292 in the CAP cohort for the analysis. Mortality ranged between 4 and 32% (0 to 3 abnormal biomarkers) and 0-9% in SARS-CoV-2 pneumonia and CAP, respectively. In the first COVID-19 cohort, adjusted for age and sex, we observed an increased odds ratio for in-hospital mortality in COVID-19 with elevated biomarkers altered (OR 1.8, 3, and 6.3 with 1, 2, and 3 abnormal biomarkers, respectively). The model had an AUROC of 0.83. Comparable findings were found for ICU admission, with an AUROC of 0.76. These results were confirmed in the other COVID-19 cohorts Similar OR trends were reported in the CAP cohort; however, results were not statistically significant. Assessing the host response via accessible biomarkers is a simple and rapidly applicable approach for pneumonia.


Subject(s)
COVID-19 , Community-Acquired Infections , Hospital Mortality , Humans , COVID-19/mortality , COVID-19/immunology , COVID-19/virology , Community-Acquired Infections/mortality , Community-Acquired Infections/virology , Male , Female , Middle Aged , Aged , C-Reactive Protein/analysis , C-Reactive Protein/metabolism , SARS-CoV-2 , Intensive Care Units , Biomarkers/blood , Risk Assessment/methods , Lymphocyte Count , Severity of Illness Index , Aged, 80 and over , Pneumonia/mortality , Pneumonia/virology
3.
J Antimicrob Chemother ; 79(5): 959-961, 2024 May 02.
Article in English | MEDLINE | ID: mdl-38693426

ABSTRACT

Community-acquired pneumonia continues to be one of the most common causes of morbidity and mortality due to infectious disease. The aetiologies, clinical presentations, diagnostic modalities and therapeutic options are changing and outpacing the creation of management guidelines. This educational article summarizes a roundtable activity sponsored by an unrestricted educational grant by Paratek that included US experts discussing these changes and identifying gaps in the current guidelines.


Subject(s)
Community-Acquired Infections , Pneumonia , Practice Guidelines as Topic , Community-Acquired Infections/diagnosis , Community-Acquired Infections/drug therapy , Humans , United States , Pneumonia/diagnosis , Pneumonia/therapy , Pneumonia/drug therapy , Anti-Bacterial Agents/therapeutic use
5.
Narra J ; 4(1): e587, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38798843

ABSTRACT

Leptospirosis is an uncommon infectious illness - a spirochetal zoonosis - caused by Leptospira species and the primary cause of human leptospirosis is exposure to the urine of infected rodents. Clinical manifestations of human leptospirosis are diverse, ranging from asymptomatic infection to severe life-threatening with multiorgan dysfunction. The severe condition is known as Weil's disease, which is characterized by feverish illness with jaundice, acute kidney damage, and bleeding. The aim of this case report was to present a Weil's disease which occurred simultaneously with a community-acquired pneumonia (CAP) resulting in serious complications. A 41-year-old man with Weil's disease, as well as CAP caused by Streptococcus pneumoniae, and septic shock was presented. The patient was treated accordingly after establishing the diagnosis through history taking, physical examination, and laboratory tests. In this instance, the score for diagnosing leptospirosis based on Modified Faine's Criteria was calculated resulting possible diagnoses; and therefore, therapeutic management was initiated. Despite presenting with severe symptoms, the patient recovered completely after receiving antibiotics and supportive care. This study highlights that when a patient has Weil's disease and a CAP infection, which could cause unfavorable consequence, a prompt diagnosis and proper treatment could result satisfied patient recovery.


Subject(s)
Community-Acquired Infections , Multiple Organ Failure , Shock, Septic , Weil Disease , Humans , Adult , Male , Shock, Septic/diagnosis , Shock, Septic/microbiology , Community-Acquired Infections/diagnosis , Community-Acquired Infections/microbiology , Multiple Organ Failure/diagnosis , Weil Disease/diagnosis , Anti-Bacterial Agents/therapeutic use , Pneumonia/diagnosis , Pneumonia/microbiology
6.
Pediatr Infect Dis J ; 43(2): e67-e70, 2024 Feb 01.
Article in English | MEDLINE | ID: mdl-38758207

ABSTRACT

We evaluated whether the quantification of IgG to pneumococcal capsular polysaccharides is an accurate diagnostic test for pneumococcal infection in children with pneumonia in Nepal. Children with pneumococcal pneumonia did not have higher convalescent, or higher fold change, IgG to pneumococcal polysaccharides than children with other causes of pneumonia. Caution is needed in interpreting antibody responses in pneumococcal infections.


Subject(s)
Antibodies, Bacterial , Community-Acquired Infections , Immunoglobulin G , Pneumonia, Pneumococcal , Polysaccharides, Bacterial , Streptococcus pneumoniae , Humans , Antibodies, Bacterial/blood , Child, Preschool , Polysaccharides, Bacterial/immunology , Immunoglobulin G/blood , Infant , Streptococcus pneumoniae/immunology , Pneumonia, Pneumococcal/diagnosis , Pneumonia, Pneumococcal/immunology , Community-Acquired Infections/diagnosis , Community-Acquired Infections/immunology , Male , Female , Child , Nepal , Bacterial Capsules/immunology
7.
Article in English | MEDLINE | ID: mdl-38747852

ABSTRACT

This study aimed to identify factors associated with colonization by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in adult patients admitted to a Brazilian hospital. This is a cross-sectional study, in which patients underwent a nasal swab and were asked about hygiene behavior, habits, and clinical history. Among the 702 patients, 180 (25.6%) had S. aureus and 21 (2.9%) MRSA. The factors associated with MRSA colonization were attending a gym (OR 4.71; 95% CI; 1.42 - 15.06), smoking habit in the last year (OR 2.37; 95% CI; 0.88 - 6.38), previous hospitalization (OR 2.18; CI 95%; 0.89 - 5.25), and shared personal hygiene items (OR 1.99; 95% CI; 0.71 - 5.55). At the time of admission, colonization by CA-MRSA isolates was higher than that found in the general population. This can be an important public health problem, already endemic in hospitals, whose factors such as those associated with habits (smoking cigarettes) and behaviors (team sports practice and activities in gyms) have been strongly highlighted. These findings may help developing infection control policies, allowing targeting patients on higher-risk populations for MRSA colonization.


Subject(s)
Community-Acquired Infections , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections , Humans , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Cross-Sectional Studies , Male , Female , Staphylococcal Infections/microbiology , Community-Acquired Infections/microbiology , Middle Aged , Adult , Risk Factors , Brazil/epidemiology , Young Adult , Aged , Socioeconomic Factors , Carrier State/microbiology , Adolescent
8.
Dtsch Med Wochenschr ; 149(12): 714-718, 2024 Jun.
Article in German | MEDLINE | ID: mdl-38781995

ABSTRACT

In the case of septic shock, recent studies show benefits from a combination of hydrocortisone and fludrocortisone, but clear guideline recommendations are still lacking. For severe community-acquired pneumonia, early corticosteroid therapy is recommended. Corticosteroid therapy should not be used in influenza-associated community-acquired pneumonia. In contrast, a significantly lower 28-day mortality rate was observed for COVID-19 by the use of dexamethasone. Current guidelines also recommend the use of corticosteroids in Acute Respiratory Distress Syndrome. These recommendations are based primarily on studies that started steroid therapy early. However, many questions such as the type of corticosteroid, the timing and duration of therapy, and the dosage still remain unanswered.


Subject(s)
Adrenal Cortex Hormones , Critical Care , Humans , Adrenal Cortex Hormones/therapeutic use , Adrenal Cortex Hormones/adverse effects , Shock, Septic/drug therapy , Respiratory Distress Syndrome/drug therapy , Respiratory Distress Syndrome/mortality , Community-Acquired Infections/drug therapy , COVID-19/mortality , COVID-19 Drug Treatment , Dexamethasone/therapeutic use , Hydrocortisone/therapeutic use , Practice Guidelines as Topic
9.
Sci Rep ; 14(1): 11846, 2024 05 24.
Article in English | MEDLINE | ID: mdl-38783029

ABSTRACT

Community-acquired pneumonia (CAP) poses a significant global health challenge, prompting exploration of innovative treatments. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of vitamin C supplementation in adults undergoing treatment for CAP. A comprehensive search of the MEDLINE, Embase, CINAHL, the Cochrane Central Register of Controlled Trials, and Clinical Trials.gov databases from inception to 17 November 2023 identified six randomized-controlled-trials (RCTs) meeting inclusion criteria. The primary outcome analysis revealed a non-significant trend towards reduced overall mortality in the vitamin C group compared to controls (RR 0.51; 95% CI 0.24 to 1.09; p = 0.052; I2 = 0; p = 0.65). Sensitivity analysis, excluding corona-virus-disease 2019 (COVID-19) studies and considering the route of vitamin C administration, confirmed this trend. Secondary outcomes, including hospital length-of-stay (LOS), intensive-care-unit (ICU) LOS, and mechanical ventilation, exhibited mixed results. Notably, heterogeneity and publication bias were observed in hospital LOS analysis, necessitating cautious interpretation. Adverse effects were minimal, with isolated incidents of nausea, vomiting, hypotension, and tachycardia reported. This meta-analysis suggests potential benefits of vitamin C supplementation in CAP treatment. However, inconclusive findings and methodological limitations warrants cautious interpretation, emphasising the urgency for high-quality trials to elucidate the true impact of vitamin C supplementation in CAP management.


Subject(s)
Ascorbic Acid , Community-Acquired Infections , Dietary Supplements , Pneumonia , Humans , Ascorbic Acid/therapeutic use , Ascorbic Acid/administration & dosage , Community-Acquired Infections/drug therapy , Pneumonia/drug therapy , Treatment Outcome , Randomized Controlled Trials as Topic , Length of Stay , COVID-19 , Respiration, Artificial
10.
BMC Infect Dis ; 24(1): 518, 2024 May 23.
Article in English | MEDLINE | ID: mdl-38783190

ABSTRACT

BACKGROUND: It is important to determine the prevalence and prognosis of community-acquired infection (CAI) and nosocomial infection (NI) to develop treatment strategies and appropriate medical policies in aging society. METHODS: Patients hospitalized between January 2010 and December 2019, for whom culture tests were performed and antibiotics were administered, were selected using a national claims-based database. The annual trends in incidence and in-hospital mortality were calculated and evaluated by dividing the patients into four age groups. RESULTS: Of the 73,962,409 inpatients registered in the database, 9.7% and 4.7% had CAI and NI, respectively. These incidences tended to increase across the years in both the groups. Among the patients hospitalized with infectious diseases, there was a significant increase in patients aged ≥ 85 years (CAI: + 1.04%/year and NI: + 0.94%/year, P < 0.001), while there was a significant decrease in hospitalization of patients aged ≤ 64 years (CAI: -1.63%/year and NI: -0.94%/year, P < 0.001). In-hospital mortality was significantly higher in the NI than in the CAI group (CAI: 8.3%; NI: 14.5%, adjusted mean difference 4.7%). The NI group had higher organ support, medical cost per patient, and longer duration of hospital stay. A decreasing trend in mortality was observed in both the groups (CAI: -0.53%/year and NI: -0.72%/year, P < 0.001). CONCLUSION: The present analysis of a large Japanese claims database showed that NI is a significant burden on hospitalized patients in aging societies, emphasizing the need to address particularly on NI.


Subject(s)
Community-Acquired Infections , Cross Infection , Databases, Factual , Hospital Mortality , Humans , Japan/epidemiology , Aged , Male , Female , Community-Acquired Infections/mortality , Community-Acquired Infections/epidemiology , Middle Aged , Aged, 80 and over , Cross Infection/mortality , Cross Infection/epidemiology , Incidence , Adult , Hospitalization/statistics & numerical data , Young Adult , Adolescent
11.
Medicine (Baltimore) ; 103(21): e38248, 2024 May 24.
Article in English | MEDLINE | ID: mdl-38788007

ABSTRACT

The spread of multidrug-resistant organisms (MDROs) has resulted in a corresponding increase in the incidence of urinary tract infections (UTIs). The risk factors and hospitalization burden for community-acquired MDRO-associated UTIs are discussed herein. This retrospective study included 278 patients with community-based MDRO-associated UTIs from January 2020 to January 2022. The MDRO (n = 139) and non-MDRO groups (n = 139) were separated based on drug susceptibility results. Community-based MDRO-associated UTIs mainly occurred in the elderly and frail patients with a history of invasive urinary tract procedures. The MDRO group imposed a greater economic burden compared to the non-MDRO group. Independent risk factors for community-based MDRO-associated UTIs were as follows: white blood cell (WBC) count > 10.0 × 109/L (OR = 2.316, 95% CI = 1.316-3.252; P = .018); ≥3 kinds of urinary tract obstructive diseases (OR = 1.720, 95% CI = 1.004-2.947; P = .048); use of 3rd generation cephalosporins (OR = 2.316, 95% CI = 1.316-4.076; P = .004); and a history of invasive urologic procedures (OR = 2.652, 95% CI = 1.567-4.487; P < .001). Days of hospitalization, antibiotic use, and bladder catheter use were significantly greater in the MDRO group than the non-MDRO group (P < .05).


Subject(s)
Community-Acquired Infections , Drug Resistance, Multiple, Bacterial , Urinary Tract Infections , Humans , Urinary Tract Infections/epidemiology , Urinary Tract Infections/microbiology , Urinary Tract Infections/drug therapy , Urinary Tract Infections/economics , Retrospective Studies , Male , Community-Acquired Infections/epidemiology , Community-Acquired Infections/economics , Community-Acquired Infections/microbiology , Female , Risk Factors , Aged , Middle Aged , Hospitalization/economics , Hospitalization/statistics & numerical data , Anti-Bacterial Agents/therapeutic use , Aged, 80 and over , Cost of Illness , Adult
12.
Ann Intern Med ; 177(5): JC51, 2024 May.
Article in English | MEDLINE | ID: mdl-38710079

ABSTRACT

SOURCE CITATION: Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024;12:294-304. 38184008.


Subject(s)
Anti-Bacterial Agents , Clarithromycin , Community-Acquired Infections , Humans , Clarithromycin/administration & dosage , Clarithromycin/therapeutic use , Community-Acquired Infections/drug therapy , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Double-Blind Method , Administration, Oral , Pneumonia/drug therapy , Male , Female , Pneumonia, Bacterial/drug therapy , Middle Aged , Drug Therapy, Combination
13.
Ann Intern Med ; 177(5): JC50, 2024 May.
Article in English | MEDLINE | ID: mdl-38710088

ABSTRACT

SOURCE CITATION: Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit Care Med. 2024;52:e219-e233. 38240492.


Subject(s)
Adrenal Cortex Hormones , Community-Acquired Infections , Respiratory Distress Syndrome , Sepsis , Humans , Respiratory Distress Syndrome/drug therapy , Sepsis/drug therapy , Adrenal Cortex Hormones/therapeutic use , Community-Acquired Infections/drug therapy , Pneumonia/drug therapy , Adult
14.
Article in English | MEDLINE | ID: mdl-38765535

ABSTRACT

Objective: The aim of this study is to evaluate the etiological profile and antimicrobial resistance in breast abscess cultures from patients from the community, treated at a public hospital located in Porto Alegre, Brazil. Methods: This is an retrospective cross-sectional study that evaluated the medical records of patients with bacterial isolates in breast abscess secretion cultures and their antibiograms, from January 2010 to August 2022. Results: Based on 129 positive cultures from women from the community diagnosed with breast abscesses and treated at Fêmina Hospital, 99 (76.7%) of the patients had positive cultures for Staphylococcus sp, 91 (92%) of which were cases of Staphylococcus aureus. Regarding the resistance profile of S. aureus, 32% of the strains were resistant to clindamycin, 26% to oxacillin and 5% to trimethoprim-sulfamethoxazole. The antimicrobials vancomycin, linezolid and tigecycline did not show resistance for S. aureus. Conclusion: Staphylococcus aureus was the most common pathogen found in the breast abscess isolates during the study period. Oxacillin remains a good option for hospitalized patients. The use of sulfamethoxazole plus trimethoprim should be considered as a good option for use at home, due to its low bacterial resistance, effectiveness and low cost.


Subject(s)
Abscess , Anti-Bacterial Agents , Humans , Female , Cross-Sectional Studies , Retrospective Studies , Abscess/microbiology , Adult , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Middle Aged , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Brazil , Staphylococcal Infections/microbiology , Staphylococcal Infections/drug therapy , Microbial Sensitivity Tests , Drug Resistance, Bacterial , Breast Diseases/microbiology , Breast Diseases/drug therapy , Young Adult , Community-Acquired Infections/microbiology , Community-Acquired Infections/drug therapy , Adolescent
15.
PLoS One ; 19(5): e0299257, 2024.
Article in English | MEDLINE | ID: mdl-38696394

ABSTRACT

BACKGROUND: Acute kidney injury (AKI) is a common and severe complication in patients treated at an Intensive Care Unit (ICU). The pathogenesis of AKI has been reported to involve hypoperfusion, diminished oxygenation, systemic inflammation, and damage by increased intracellular iron concentration. Hepcidin, a regulator of iron metabolism, has been shown to be associated with sepsis and septic shock, conditions that can result in AKI. Heparin binding protein (HBP) has been reported to be associated with sepsis and AKI. The aim of the present study was to compare serum hepcidin and heparin binding protein (HBP) levels in relation to AKI in patients admitted to the ICU. METHODS: One hundred and forty patients with community acquired illness admitted to the ICU within 24 hours after first arrival to the hospital were included in the study. Eighty five of these patients were diagnosed with sepsis and 55 with other severe non-septic conditions. Logistic and linear regression models were created to evaluate possible correlations between circulating hepcidin and heparin-binding protein (HBP), stage 2-3 AKI, peak serum creatinine levels, and the need for renal replacement therapy (RRT). RESULTS: During the 7-day study period, 52% of the 85 sepsis and 33% of the 55 non-sepsis patients had been diagnosed with AKI stage 2-3 already at inclusion. The need for RRT was 20% and 15%, respectively, in the groups. Hepcidin levels at admission were significantly higher in the sepsis group compared to the non-sepsis group but these levels did not significantly correlate to the development of stage 2-3 AKI in the sepsis group (p = 0.189) nor in the non-sepsis group (p = 0.910). No significant correlation between hepcidin and peak creatinine levels, nor with the need for RRT was observed. Stage 2-3 AKI correlated, as expected, significantly with HBP levels at admission in both groups (Odds Ratio 1.008 (CI 1.003-1.014, p = 0.005), the need for RRT, as well as with peak creatinine in septic patients. CONCLUSION: Initial serum hepcidin, and HBP levels in patients admitted to the ICU are biomarkers for septic shock but in contrast to HBP, hepcidin does not portend progression of disease into AKI or a later need for RRT. Since hepcidin is a key regulator of iron metabolism our present data do not support a decisive role of initial iron levels in the progression of septic shock into AKI.


Subject(s)
Acute Kidney Injury , Antimicrobial Cationic Peptides , Blood Proteins , Hepcidins , Shock, Septic , Humans , Acute Kidney Injury/blood , Acute Kidney Injury/etiology , Hepcidins/blood , Male , Female , Shock, Septic/blood , Shock, Septic/complications , Aged , Middle Aged , Blood Proteins/metabolism , Carrier Proteins/blood , Community-Acquired Infections/complications , Community-Acquired Infections/blood , Biomarkers/blood , Intensive Care Units , Creatinine/blood , Aged, 80 and over
16.
Sci Rep ; 14(1): 10758, 2024 05 10.
Article in English | MEDLINE | ID: mdl-38730020

ABSTRACT

Staphylococcus aureus is a frequent agent of bacteraemia. This bacterium has a variety of virulence traits that allow the establishment and maintenance of infection. This study explored the virulence profile of S. aureus strains causing paediatric bacteraemia (SAB) in Manhiça district, Mozambique. We analysed 336 S. aureus strains isolated from blood cultures of children younger than 5 years admitted to the Manhiça District Hospital between 2001 and 2019, previously characterized for antibiotic susceptibility and clonality. The strains virulence potential was evaluated by PCR detection of the Panton-Valentine leucocidin (PVL) encoding genes, lukS-PV/lukF-PV, assessment of the capacity for biofilm formation and pathogenicity assays in Galleria mellonella. The overall carriage of PVL-encoding genes was over 40%, although reaching ~ 70 to 100% in the last years (2014 to 2019), potentially linked to the emergence of CC152 lineage. Strong biofilm production was a frequent trait of CC152 strains. Representative CC152 and CC121 strains showed higher virulence potential in the G. mellonella model when compared to reference strains, with variations within and between CCs. Our results highlight the importance of monitoring the emergent CC152-MSSA-PVL+ and other lineages, as they display important virulence traits that may negatively impact the management of SAB paediatric patients in Manhiça district, Mozambique.


Subject(s)
Bacteremia , Biofilms , Community-Acquired Infections , Staphylococcal Infections , Staphylococcus aureus , Humans , Mozambique/epidemiology , Staphylococcus aureus/genetics , Staphylococcus aureus/pathogenicity , Staphylococcus aureus/isolation & purification , Virulence/genetics , Staphylococcal Infections/microbiology , Staphylococcal Infections/epidemiology , Biofilms/growth & development , Child, Preschool , Bacteremia/microbiology , Bacteremia/epidemiology , Community-Acquired Infections/microbiology , Infant , Animals , Exotoxins/genetics , Bacterial Toxins/genetics , Leukocidins/genetics , Virulence Factors/genetics , Female , Male , Moths/microbiology
17.
BMC Pulm Med ; 24(1): 259, 2024 May 26.
Article in English | MEDLINE | ID: mdl-38797852

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has changed respiratory infection patterns globally. However, its impact on community-acquired pneumonia (CAP) in high-risk patients with haematological malignancies (HM) is uncertain. We aimed to examine how community-acquired pneumonia aetiology in patients with haematological malignancies changed during the COVID-19 pandemic. METHODS: This was a retrospective study that included 524 patients with haematological malignancies hospitalised with community-acquired pneumonia between March 2018 and February 2022. Patients who underwent bronchoscopy within 24 h of admission to identify community-acquired pneumonia aetiology were included. Data on patient characteristics, laboratory findings, and results of bronchioalveolar lavage fluid cultures and polymerase chain reaction tests were analysed and compared to identify changes and in-hospital mortality risk factors. RESULTS: Patients were divided into the 'pre-COVID-19 era' (44.5%) and 'COVID-19 era' (55.5%) groups. The incidence of viral community-acquired pneumonia significantly decreased in the COVID-19 era, particularly for influenza A, parainfluenza, adenovirus, and rhinovirus (pre-COVID-19 era vs. COVID-19 era: 3.0% vs. 0.3%, P = 0.036; 6.5% vs. 0.7%, P = 0.001; 5.6% vs. 1.4%, P = 0.015; and 9.5% vs. 1.7%, P < 0.001, respectively), whereas that of bacterial, fungal, and unknown community-acquired pneumonia aetiologies remain unchanged. Higher Sequential Organ Failure Assessment scores and lower platelet counts correlated with in-hospital mortality after adjusting for potential confounding factors. CONCLUSIONS: In the COVID-19 era, the incidence of community-acquired pneumonia with viral aetiologies markedly decreased among patients with haematological malignancies, with no changes in the incidence of bacterial and fungal pneumonia. Further studies are required to evaluate the impact of COVID-19 on the prognosis of patients with haematological malignancies and community-acquired pneumonia.


Subject(s)
COVID-19 , Community-Acquired Infections , Hematologic Neoplasms , Humans , COVID-19/epidemiology , COVID-19/complications , Male , Female , Retrospective Studies , Hematologic Neoplasms/complications , Middle Aged , Community-Acquired Infections/epidemiology , Aged , Hospital Mortality , SARS-CoV-2 , Risk Factors , Incidence , Adult , Hospitalization/statistics & numerical data , Pneumonia, Viral/epidemiology , Pneumonia, Viral/complications
18.
J Bras Pneumol ; 50(2): e20230329, 2024.
Article in English | MEDLINE | ID: mdl-38808825

ABSTRACT

OBJECTIVE: To assess differences in the sputum microbiota of community-acquired pneumonia (CAP) patients with either COPD or asthma, specifically focusing on a patient population in Turkey. METHODS: This retrospective study included hospitalized patients > 18 years of age with a diagnosis of pneumonia between January of 2021 and January of 2023. Participants were recruited from two hospitals, and three patient groups were considered: CAP patients with asthma, CAP patients with COPD, and CAP patients without COPD or asthma. RESULTS: A total of 246 patients with CAP were included in the study, 184 (74.8%) and 62 (25.2%) being males and females, with a mean age of 66 ± 14 years. Among the participants, 52.9% had COPD, 14.2% had asthma, and 32.9% had CAP but no COPD or asthma. Upon analysis of sputum cultures, positive sputum culture growth was observed in 52.9% of patients. The most commonly isolated microorganisms were Pseudomonas aeruginosa (n = 40), Acinetobacter baumannii (n = 20), Klebsiella pneumoniae (n = 16), and Moraxella catarrhalis (n = 8). CAP patients with COPD were more likely to have a positive sputum culture (p = 0.038), a history of antibiotic use within the past three months (p = 0.03), utilization of long-term home oxygen therapy (p < 0.001), and use of noninvasive ventilation (p = 0.001) when compared with the other patient groups. Additionally, CAP patients with COPD had a higher CURB-65 score when compared with CAP patients with asthma (p = 0.004). CONCLUSIONS: This study demonstrates that CAP patients with COPD tend to have more severe presentations, while CAP patients with asthma show varied microbial profiles, underscoring the need for patient-specific management strategies in CAP.


Subject(s)
Asthma , Community-Acquired Infections , Microbiota , Pulmonary Disease, Chronic Obstructive , Sputum , Humans , Female , Male , Sputum/microbiology , Asthma/microbiology , Pulmonary Disease, Chronic Obstructive/microbiology , Retrospective Studies , Community-Acquired Infections/microbiology , Aged , Middle Aged , Hospitalization , Turkey , Aged, 80 and over , Pneumonia/microbiology , Pneumonia, Bacterial/microbiology
19.
Respir Res ; 25(1): 223, 2024 May 29.
Article in English | MEDLINE | ID: mdl-38811936

ABSTRACT

BACKGROUND: Community-acquired pneumonia (CAP) is a common and serious condition that can be caused by a variety of pathogens. However, much remains unknown about how these pathogens interact with the lower respiratory commensals, and whether any correlation exists between the dysbiosis of the lower respiratory microbiota and disease severity and prognosis. METHODS: We conducted a retrospective cohort study to investigate the composition and dynamics of sputum microbiota in patients diagnosed with CAP. In total, 917 sputum specimens were collected consecutively from 350 CAP inpatients enrolled in six hospitals following admission. The V3-V4 region of the 16 S rRNA gene was then sequenced. RESULTS: The sputum microbiota in 71% of the samples were predominately composed of respiratory commensals. Conversely, 15% of the samples demonstrated dominance by five opportunistic pathogens. Additionally, 5% of the samples exhibited sterility, resembling the composition of negative controls. Compared to non-severe CAP patients, severe cases exhibited a more disrupted sputum microbiota, characterized by the highly dominant presence of potential pathogens, greater deviation from a healthy state, more significant alterations during hospitalization, and sparser bacterial interactions. The sputum microbiota on admission demonstrated a moderate prediction of disease severity (AUC = 0.74). Furthermore, different pathogenic infections were associated with specific microbiota alterations. Acinetobacter and Pseudomonas were more abundant in influenza A infections, with Acinetobacter was also enriched in Klebsiella pneumoniae infections. CONCLUSION: Collectively, our study demonstrated that pneumonia may not consistently correlate with severe dysbiosis of the respiratory microbiota. Instead, the degree of microbiota dysbiosis was correlated with disease severity in CAP patients.


Subject(s)
Community-Acquired Infections , Microbiota , Severity of Illness Index , Sputum , Humans , Community-Acquired Infections/microbiology , Community-Acquired Infections/diagnosis , Community-Acquired Infections/epidemiology , Male , Female , Sputum/microbiology , Middle Aged , Aged , Retrospective Studies , Longitudinal Studies , Cohort Studies , Dysbiosis/microbiology , Dysbiosis/diagnosis , Pneumonia/microbiology , Pneumonia/diagnosis , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/epidemiology , Aged, 80 and over , Adult
20.
Emerg Infect Dis ; 30(6): 1088-1095, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38781685

ABSTRACT

The characteristics of severe human parainfluenza virus (HPIV)-associated pneumonia in adults have not been well evaluated. We investigated epidemiologic and clinical characteristics of 143 patients with severe HPIV-associated pneumonia during 2010-2019. HPIV was the most common cause (25.2%) of severe virus-associated hospital-acquired pneumonia and the third most common cause (15.7%) of severe virus-associated community-acquired pneumonia. Hematologic malignancy (35.0%), diabetes mellitus (23.8%), and structural lung disease (21.0%) were common underlying conditions. Co-infections occurred in 54.5% of patients admitted to an intensive care unit. The 90-day mortality rate for HPIV-associated pneumonia was comparable to that for severe influenza virus-associated pneumonia (55.2% vs. 48.4%; p = 0.22). Ribavirin treatment was not associated with lower mortality rates. Fungal co-infections were associated with 82.4% of deaths. Clinicians should consider the possibility of pathogenic co-infections in patients with HPIV-associated pneumonia. Contact precautions and environmental cleaning are crucial to prevent HPIV transmission in hospital settings.


Subject(s)
Community-Acquired Infections , Tertiary Care Centers , Humans , Male , Female , Middle Aged , Community-Acquired Infections/epidemiology , Community-Acquired Infections/virology , Republic of Korea/epidemiology , Aged , Adult , Healthcare-Associated Pneumonia/epidemiology , Pneumonia, Viral/epidemiology , Pneumonia, Viral/mortality , Coinfection/epidemiology , Paramyxoviridae Infections/epidemiology , Paramyxoviridae Infections/mortality , History, 21st Century , Cross Infection/epidemiology , Young Adult , Aged, 80 and over
SELECTION OF CITATIONS
SEARCH DETAIL
...